4,901 trials
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
Chronic Renal Insufficiency · Type 2 Diabetes Mellitus
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin — 4703.16; 4983.58; 5785.21; 4312.17 nM*hr
Waldenstrom's Macroglobulinemia · Non-Hodgkin's Lymphoma · Hodgkin's Disease
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0; 0; 0 participants
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Healthy Volunteers
Primary: Part 1: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385 — 2.0; 2.0 hours
Bioequivalence, AUC, Cmax, Pharmacokinetics
Primary: Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1.05; 0.992; 1.09 ng*h/mL
Cancer
Primary: Psychological Distress — 2.25; -.65 units on a scale — p=0.14
Hepatitis C
Primary: Maximum Observed Plasma Concentration (Cmax) for Daclatasvir — 1335; 493; 1412; 476 ng/mL
Rheumatoid Arthritis
Primary: Adjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population — 11.5; 12.6…
Solid Tumor
Primary: Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab — 75.0 mg/m^2
Coronary Artery Disease
Primary: Safety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Events — 10; 10; 0; 2 participants
Obesity · Obesity, Morbid · Pregnancy
Primary: Anti Xa Level — 0.14; 0.30 IU/mL
Non Hematologic Cancers
Primary: Assess the Safety and Tolerability of Defactinib (VS-6063) in Japanese Subjects With Non-hematologic Malignancies — 3; 3; 3; 3 participants
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration — 895; 986 ng/mL
Prostate Adenocarcinoma
Primary: Partial Response in Bone Scan From Baseline to Week 6 — 9; 1; 6 participants